Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
Status:
Recruiting
Trial end date:
2024-01-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well ixazomib, gemcitabine, and doxorubicin work in treating
patients with kidney cancer that has spread to other places in the body (locally advanced or
metastatic). Ixazomib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Drugs used in chemotherapy, such as gemcitabine and doxorubicin, work
in different ways to stop the growth of tumor cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Giving ixazomib, gemcitabine, and
doxorubicin may work better in treating patients with kidney cancer.